Orchestra BioMed (NASDAQ: OBIO) insider transactions
In the twelve months to 10 November 2026, executives and directors of Orchestra BioMed reported 7 open-market sales of 90,032 shares ($439,182) and 13 open-market purchases of 112,636 shares ($509,891), by 7 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 9 November 2026 | Taylor Andrew Lawrence | Chief Financial Officer | Open-market purchase | +1,000 | $5.00 | 590,989 | Form 4 |
| 9 November 2026 | Hochman David P | See Remarks | Open-market purchase | +5,000 | $5.00 | 437,916 | Form 4 |
| 9 November 2026 | Pacitti David | Director | Open-market purchase | +20,000 | $5.00 | 74,750 | Form 4 |
| 9 November 2026 | Fain Eric S | Director | Open-market purchase | +20,000 | $5.00 | 119,630 | Form 4 |
| 2 November 2026 | Sherman Darren | See Remarks | Open-market sale, 10b5-1 plan | −15,000 | $5.74 | 1,104,402 | Form 4 |
| 1 October 2026 | Sherman Darren | See Remarks | Open-market sale, 10b5-1 plan | −15,000 | $6.36 | 1,119,402 | Form 4 |
| 10 September 2026 | Hochman David P | See Remarks | Shares withheld for tax | −3,283 | $5.81 | 1,067,463 | Form 4 |
| 10 September 2026 | Hochman David P | See Remarks | Shares withheld for tax | −3,283 | $5.81 | 432,916 | Form 4 |
| 3 September 2026 | Hochman David P | See Remarks | Open-market purchase | +10,000 | $4.79 | 1,070,746 | Form 4 |
| 1 September 2026 | Sherman Darren | See Remarks | Open-market sale, 10b5-1 plan | −15,000 | $4.94 | 1,134,402 | Form 4 |
| 26 August 2026 | Aiello Joshua | Principal Accounting Officer | Shares withheld for tax | −203 | $5.26 | 18,441 | Form 4 |
| 26 August 2026 | Sherman Darren | See Remarks | Shares withheld for tax | −4,925 | $5.26 | 1,149,402 | Form 4 |
| 26 August 2026 | Sherman Darren | See Remarks | Open-market purchase | +2,000 | $5.33 | 2,000 | Form 4 |
| 26 August 2026 | Taylor Andrew Lawrence | Chief Financial Officer | Shares withheld for tax | −3,076 | $5.26 | 589,989 | Form 4 |
| 12 August 2026 | Cleary Chris | Director | Shares withheld for tax | −4,238 | $4.42 | 29,153 | Form 4 |
| 12 August 2026 | Mack John Prosper | Director | Shares withheld for tax | −4,885 | $4.42 | 66,544 | Form 4 |
| 12 August 2026 | Fain Eric S | Director | Shares withheld for tax | −5,145 | $4.42 | 99,630 | Form 4 |
| 12 August 2026 | Pacitti David | Director | Shares withheld for tax | −3,761 | $4.42 | 54,750 | Form 4 |
| 3 August 2026 | Sherman Darren | See Remarks | Open-market sale, 10b5-1 plan | −15,000 | $4.09 | 1,154,327 | Form 4 |
| 1 July 2026 | Sherman Darren | See Remarks | Open-market sale, 10b5-1 plan | −15,000 | $4.27 | 1,169,327 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Orchestra BioMed page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.